Karyopharm Therapeutics reported its Q2 2025 financial results, revealing a 6% increase in net product revenue for XPOVIO, totaling $29.7 million, despite a decline in total revenue to $37.9 million due to reduced one-time licensing income. The company is navigating financial constraints with an upcoming debt maturity in October, while managing to cut R&D and SG&A expenses by 15% and 8%, respectively. Notably, royalty revenues surged by 28%, indicating strong global demand through partnerships.
The company is focused on its Phase III SENTRY trial for myelofibrosis, with preliminary safety data suggesting improved tolerability for the combination of selinexor and ruxolitinib compared to ruxolitinib alone. Management anticipates peak annual revenue potential of up to $1 billion for selinexor in the U.S. alone, contingent on successful trial outcomes and regulatory approval.
Investors should monitor Karyopharm’s liquidity situation closely, as its ability to fund operations into early 2026 hinges on upcoming refinancing efforts and trial results that could significantly impact its market position.
Source: fool.com